natgillin/translations-raw huggingface dataset:
The Member States shall ensure that the MAH shall set up a surveillance programme/registry to collect information on the demographics, safety and outcome data from patients prescribed Tracleer to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. 
Države članice zagotovijo, da IDIZ vzpostavi program/register nadzorovanja za zbiranje informacij o učinkih ter demografskih in varnostnih podatkih bolnikov, ki jim je bilo predpisano zdravilo Tracleer, da se zmanjša število novih razjed prstov pri bolnikih s sistemsko sklerozo ter dolgotrajno boleznijo razjed prstov.
• That women of child bearing potential must use effective contraception 
• da morajo ženske v rodni dobi jemati učinkovito kontracepcijo
• That Tracleer is teratogenic in animals 
• da je zdravilo Tracleer teratogeno za živali
The MAH shall agree the details of a controlled distribution system with the National Competent Authorities and must implement such programme nationally to ensure that prior to prescribing all health care professionals who intend to prescribe and/or dispense Tracleer are provided with a Prescriber Kit containing the following: 
IDIZ se o podrobnostih nadzorovanega distribucijskega sistema dogovori s pristojnimi državnimi organi in mora tak program izvajati nacionalno in tako zagotovi, da imajo vsi strokovnjaki zdravstvenega varstva, ki nameravajo predpisati in/ali izdati zdravilo Tracleer, že pred predpisovanjem zagotovljeno opremo za predpisovanje, ki vsebuje:
• Patient Information Booklet/Patient Reminder Card 
• navodilo za uporabo/kartico Opozorila za bolnika
• That Tracleer causes a decrease in haemoglobin and the need for regular blood tests 
• da zdravilo Tracleer povzroča znižanje hemoglobina in je potrebno redno izvajati krvne analize
• That Tracleer is hepatotoxic and the need for regular monitoring of liver function 
• da je zdravilo Tracleer hepatotoksično in je potrebno redno spremljati delovanje jeter
The MAH shall agree with each National Competent Authority the content of a "Reminder Letter" to all known prescribers of Tracleer, reminding them of the safety concerns with Tracleer in relation to pregnancy. 
Imetnik dovoljenja za promet z zdravilom bo skupaj z nacionalnim pristojnim organom določil vsebino "Opomnika", s katerim bo vse zdravnike, za katere je znano, da predpisujejo zdravilo Tracleer, opomnil glede pomislekov v zvezi z varnostjo zdravila Tracleer med nosečnostjo.
12 hours before your operation. 
12 ur po operaciji.
Operation or periods of limited mobility due to an illness 
Ob operacijah ali obdobjih omejene mobilnosti zaradi bolezni
Do not use this medicine if you notice {description of the visible signs of deterioration}. 
Tega zdravila ne uporabite, če opazite {opis vidnih znakov kvarjenja}.
• Benzyl alcohol 
• Benzilalkohol
Pharmacotherapeutic group: Antithrombotic agent, heparin group, ATC code: B01A B05 
Farmakoterapevtska skupina: antitrombotiki, heparinska skupina, oznaka ATC: B01A B05
(subcutaneous). 
(subkutano).
This is a preservative. 
To je konzervans.
swelling of your lips, face, throat or tongue. 
oteklost ustnic, obraza, žrela ali jezika.
Do not use this medicine after the expiry date which is stated on the label. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju.
Detailed information on this medicinal product is available on the website of {name of MS Agency (link)} 
Podrobne informacije o zdravilu so objavljene na spletni strani {ime agencije DČ (povezava)}
This reduction in the combined incidence was maintained after 30 days (from 23.3 to 19.8%; relative risk reduction of 
To zmanjšanje skupne incidence se je ohranilo po 30 dneh (s 23,3 na 19,8 %, relativno zmanjšanje tveganja 15 %).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: {DD month YYYY} Date of latest renewal: {DD month YYYY} 
Datum prve odobritve: {DD. mesec LLLL} Datum zadnjega podaljšanja: {DD. mesec LLLL}
These medicinal products differ in their manufacturing process, molecular weights, specific anti-Xa and antiIIa activities, units, dosage and clinical efficacy and safety. 
Ta zdravila se med seboj razlikujejo po postopku izdelave, molekulski masi, specifični aktivnosti anti-Xa in anti-IIa, enotah, odmerjanju ter klinični učinkovitosti in varnosti.
• When you go home, you may need to continue to use LOVENOX (and associated names) and give it yourself (see instructions below on how to do this). 
• Ko boste odšli domov, boste morda morali še naprej uporabljati zdravilo LOVENOX (in povezana imena) in si ga boste morali dajati sami (glejte spodnja navodila, kako to naredite).
DATE OF REVISION OF THE TEXT {MM/YYYY} {DD/MM/YYYY} {DD month YYYY} 
DATUM ZADNJE REVIZIJE BESEDILA {MM. LLLL} {DD/MM/LLLL} {DD. mesec LLLL}
These anticoagulant activities are mediated through anti-thrombin III (ATIII) resulting in antithrombotic activities in humans. 
Te antikoagulantne učinke posreduje antitrombin III (ATIII); posledica je antitrombotično delovanje pri človeku.
Operations and Anaesthetics 
Operacije in anestezija
If you forget to use LOVENOX (and associated names) If you forget to give yourself a dose, have it as soon as you remember. 
Če ste pozabili uporabiti zdravilo LOVENOX (in povezana imena) Če si pozabite dati odmerek, ga morate dati, čim se spomnite.
Stop using LOVENOX (and associated names) and talk to a doctor or nurse at once if you get any signs of a severe allergic reaction (such as difficulty breathing, swelling of the lips, mouth, throat or eyes). 
Nehajte uporabljati zdravilo LOVENOX (in povezana imena) in se takoj posvetujte z zdravnikom ali medicinsko sestro, če se vam pojavi kakršen koli znak hude alergijske reakcije (na primer težko dihanje, oteklost ustnic, ust, žrela ali oči).
It should not be mixed or coadministered with other medications. 
Ne smete ga mešati ali uporabiti sočasno z drugimi zdravili.
The 3,000 IU (30 mg) dose can then be directly injected into the IV line. 
3.000 i.e. (30 mg) lahko potem neposredno injicirate v intravensko linijo.
Do not give yourself a double dose on the same day to make up for a forgotten dose. 
Ne dajte si na en dan dvojnega odmerka,
This difference persisted at three months [13.8% vs 5.5% (n=23 vs 9), p=0.01]. 
Ta razlika se je ohranila tudi po treh mesecih [13,8 % v primerjavi s 5,5 % (n = 23 v primerjavi z 9), p = 0,01].
Like other similar medicines (medicines to reduce blood clotting), LOVENOX (and associated names) may cause bleeding which may potentially be life-threatening. 
Tako kot druga podobna zdravila (zdravila proti strjevanju krvi) lahko tudi zdravilo LOVENOX (in povezana imena) povzroči krvavitve, ki so lahko celo smrtno nevarne.
Multiple Dose Vials: 
Večodmerne viale:
The absolute bioavailability of enoxaparin sodium after SC injection, based on anti-Xa activity, is close to 100%. 
Absolutna biološka uporabnost natrijevega enoksaparinata po subkutani injekciji je na podlagi aktivnosti anti-Xa skoraj 100 %.
• Rare: Cutaneous vasculitis*, skin necrosis* usually occurring at the injection site (these phenomena have been usually preceded by purpura or erythematous plaques, infiltrated and painful). 
• Redki: Alopecija* • Redki: Kožni vaskulitis*, nekroza kože*, ki se po navadi pojavi na mestu injiciranja (pred temi pojavi so se po navadi razvili purpura ali infiltrirani in boleči eritematozni plaki).
Stopping blood clots forming in your blood in the following situations: 
Ustavitev nastajanja krvnih strdkov v krvi v naslednjih okoliščinah:
Withdraw 30 mL from the infusion bag with a syringe and discard the liquid. 
Iz infuzijske vrečke z brizgo odvzemite 30 ml in to tekočino zavrzite.
It is important for you to keep having LOVENOX (and associated names) injections until your doctor decides to stop them. 
Pomembno je, da injekcije zdravila LOVENOX (in povezana imena) uporabljate, dokler vam zdravnik ne naroči, da prenehajte.
Important information about some of the ingredients of LOVENOX (and associated names) LOVENOX (and associated names) contains benzyl alcohol [benzyl alcohol content to be completed nationally]. 
Pomembne informacije o nekaterih sestavinah zdravila LOVENOX (in povezana imena) Zdravilo LOVENOX (in povezana imena) vsebuje benzilalkohol [vsebnost benzilalkohola dopolni država članica].
If you stop using LOVENOX (and associated names) If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse. 
Če ste prenehali uporabljati zdravilo LOVENOX (in povezana imena) Če imate kakšna dodatna vprašanja o uporabi tega zdravila, se obrnite na zdravnika, farmacevta ali medicinsko sestro.
As benzyl alcohol may cross the placenta, it is recommended to use a formulation that does not contain benzyl alcohol. 
Benzilalkohol lahko prehaja skozi placento, zato je priporočljivo uporabiti obliko zdravila, ki ne vsebuje benzilalkohola.
Do not start treatment with LOVENOX (and associated names) until 12 hours after the final dose of direct oral anticoagulant. 
Zdravljenja z zdravilom LOVENOX (in povezana imena) ne začnite prej kot 12 ur po zadnjem odmerku neposrednega peroralnega antikoagulansa.
Should thrombocytopenia occur, it usually appears between the 5th and the 21st day following the beginning of enoxaparin sodium treatment. 
Če se trombocitopenija pojavi, se to po navadi zgodi med 5. in 21. dnem po začetku zdravljenja z natrijevim enoksaparinatom.
• An initial dose of 3,000 IU (30 mg) of LOVENOX (and associated names) will be given as injection into your vein. 
• Začetni odmerek 3.000 i.e. (30 mg) zdravila LOVENOX (in povezana imena) boste dobili kot injekcijo v veno.
LOVENOX (and associated names) contains benzyl alcohol and must not be used in newborn and premature neonates (see section 4.3). 
Zdravilo LOVENOX (in povezana imena) vsebuje benzilalkohol, zato se ga ne sme uporabljati pri novorojenčkih in nedonošenčkih (glejte poglavje 4.3).
The amount of LOVENOX (and associated names) given to you will depend on your age and the kind of heart attack you have had. 
Količina zdravila LOVENOX (in povezana imena), ki jo boste dobili, bo odvisna od vaše starosti in od vrste srčnega infarkta, ki sta jo imeli.
• If you have problems with your kidneys you may be given a smaller amount of LOVENOX (and associated names). 
• Če imate težave z ledvicami, boste lahko dobili manjšo količino zdravila LOVENOX (in povezana imena).
In order to assure the accuracy of the small volume to be injected, it is recommended to dilute the drug to 300 IU/mL (3 mg/mL). 
Da bi zagotovili točnost majhnih injiciranih količin, je zdravilo priporočljivo razredčiti na 300 i.e./ml
• Rare: Anaphylactic/Anaphylactoid reactions including shock* 
• Redki: Anafilaktične/anafilaktoidne reakcije, vključno s šokom* Bolezni živčevja
In surgical patients, haemorrhage complications were considered major: (1) if the haemorrhage caused a significant clinical event, or (2) if accompanied by a haemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. 
Pri kirurških bolnikih so bili krvavitveni zapleti ocenjeni kot hudi: (1) če je krvavitev povzročila pomemben kliničen dogodek, ali (2) če jo je spremljalo znižanje hemoglobina za ≥ 2 g/dl ali transfuzija 2 ali več enot krvnih pripravkov.
The administration of medicinal product containing benzyl alcohol as a preservative to neonates has been associated with a fatal “Gasping Syndrome” (see section 4.3). 
Uporaba zdravil, ki kot konzervans vsebujejo benzilalkohol, je bila pri novorojenčkih povezana s "sindromom hlastajočega dihanja" s smrtnim izidom (glejte poglavje 4.3).
• If you have restricted mobility due to illness, you will normally be given 4,000 IU (40 mg) of LOVENOX (and associated names) each day. 
• Če imate zaradi bolezni omejeno mobilnost, boste po navadi dobili 4.000 i.e. (40 mg) zdravila LOVENOX (in povezana imena) na dan.
The safety and efficacy of LOVENOX (and associated names) has not been evaluated in children or adolescents. 
Varnost in učinkovitost zdravila LOVENOX (in povezana imena) pri otrocih in mladostnikih nista bili ocenjeni.
• Haemorrhage As with other anticoagulants, bleeding may occur at any site. 
Tako kot pri drugih antikoagulansih se lahko kjer koli v telesu pojavi krvavitev.
• you are going to receive spinal or epidural anesthesia or lumbar puncture (see Operations and Anaesthetics): a delay should be respected between Lovenox use and this procedure. 
• če boste prejeli spinalno ali epiduralno anestezijo ali lumbalno punkcijo (glejte Operacije in anestezija): upoštevati je treba zakasnitev med uporabo zdravila Lovenox in tem postopkom.
In case of self-administration, patient should be advised to follow instructions provided in the patient information leaflet included in the pack of this medicine. 
V primeru samoinjiciranja je treba bolniku naročiti, naj upošteva navodila v navodilu za uporabo,
• IV (bolus) injection (for acute STEMI indication only): 
• Intravensko (bolusno) injiciranje (samo za indikacijo akutni STEMI):
• Stop blood clots forming in the tubes of your dialysis machine (used for people with severe kidney problems). 
• Preprečitev nastajanja krvnih strdkov v cevkah dializne naprave (uporablja se pri osebah, ki imajo hude težave z ledvicami).
enoxaparin sodium 
natrijev enoksaparinat
For patients have an operation called percutaneous coronary intervention (PCI): Depending on when you were last given LOVENOX (and associated names), your doctor may decide to give an additional dose of LOVENOX (and associated names) before a PCI operation. 
Pri bolnikih, ki so jim opravili poseg, imenovan perkutana koronarna intervencija (PKI): Odvisno od tega, kdaj ste nazadnje dobili zdravilo LOVENOX (in povezana imena), se zdravnik lahko odloči za dodaten odmerek zdravila LOVENOX (in povezana imena) pred PKI.
IV (Bolus) Injection (for acute STEMI indication only): 
Intravensko (bolusno) injiciranje (samo za indikacijo akutni STEMI):
It must not be used in premature babies or babies up to 1 month old due to the risk risk of severe toxicity including abnormal respiration. 
Pri nedonošenčkih in dojenčkih do 1 meseca starosti se ga ne sme uporabljati, ker obstaja tveganje za hude toksične učinke, vključno z nenormalnim dihanjem.
• If you have had a reaction to heparin that caused a severe drop in the number of your clotting cells (platelets) - this reaction is called heparin-induced thrombocytopeniawithin the last 100 days or if you have antibodies against enoxaparin in your blood. 
• Če ste imeli v zadnjih 100 dneh reakcijo na heparin, ki je povzročila hudo zmanjšanje števila trombocitov (krvnih ploščic) - takšno reakcijo imenujemo s heparinom izzvana trombocitopenija - ali če imate v krvi protitelesa proti enoksaparinu.
If the combination is indicated, enoxaparin sodium should be used with careful clinical and laboratory monitoring when appropriate. 
Če je kombinirano zdravljenje indicirano, je priporočljivo natrijev enoksaparinat uporabljati ob natančnem kliničnem in laboratorijskem nadzoru,
• Because of the content of benzyl alcohol (see section 6.1), enoxaparin sodium multiple dose vial formulation must not be given to newborns or premature neonates (see sections 4.4 and 4.6). 
• Zaradi vsebnosti benzilalkohola (glejte poglavje 6.1) se natrijevega enoksaparinata iz večodmernih vial ne sme dajati novorojenčkom ali nedonošenčkom (glejte poglavji 4.4 in 4.6).
Investigations • Rare: Hyperkalaemia* (see sections 4.4 and 4.5) 
Preiskave • Redki: Hiperkaliemija* (glejte poglavji 4.4 in 4.5)
• Common: Injection site haematoma, injection site pain, other injection site reaction (such as oedema, haemorrhage, hypersensitivity, inflammation, mass, pain, or reaction) 
• Pogosti: Hematom na mestu injiciranja, bolečina na mestu injiciranja, druge reakcije na mestu injiciranja (na primer edem, krvavitev, preobčutljivost, vnetje, masa, bolečina ali reakcija)
LOVENOX (and associated names) works in two ways. 
Zdravilo LOVENOX (in povezana imena) deluje na dva načina.
Benzyl alcohol may also cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old (see section 4.4). 
Benzilalkohol lahko pri dojenčkih in otrocih do 3. leta starosti povzroči tudi toksične in anafilaktoidne reakcije (glejte poglavje 4.4).
It is recommended to use the LOVENOX formulation without benzyl alcohol in pregnant women. 
Pri nosečnicah je priporočljivo uporabljati obliko zdravila LOVENOX brez benzilalkohola.
If a child accidentally injects or swallows LOVENOX (and associated names), take them to a hospital causualty department straight away. 
Če si otrok po nesreči injicira ali zaužije zdravilo LOVENOX (in povezana imena), ga nemudoma peljite v bolnišnično ambulanto za nujno pomoč.
Acetylsalicylic acid is recommended for all patients without contraindications at an initial oral loading dose of 150-300 mg (in acetylsalicylic acid-naive patients) and a maintenance dose of 75325 mg/day long-term regardless of treatment strategy. 
Acetilsalicilna kislina je priporočljiva za vse bolnike brez kontraindikacij, in sicer v začetnem peroralnem polnilnem odmerku od 150 do 300 mg (pri bolnikih, ki še niso prejemali acetilsalicilne kisline) in v vzdrževalnem odmerku od 75 do 325 mg/dan dolgoročno, ne glede na strategijo zdravljenja.
- At doses used for prophylaxis 
- V odmerkih, ki se uporabljajo za profilakso
If you are going to have a spinal puncture or an operation where an epidural or spinal anaesthetic is used, tell you doctor that you are using LOVENOX (and associated names). 
Če imate predvideno spinalno punkcijo ali operacijo, pri kateri se uporablja spinalna ali epiduralna anestezija, morate zdravniku povedati, da uporabljate zdravilo LOVENOX (in povezana imena).
When non-weight adjusted dosing was administered, it was found after a single-SC 4,000 IU (40 mg) dose, that anti-Xa exposure is 52% higher in low-weight women (<45 kg) and 27% higher in lowweight men (<57 kg) when compared to normal weight control subjects (see section 4.4). 
Če so uporabili odmerjanje, ki ni bilo korigirano za telesno maso, so po enkratnem subkutanem odmerku 4.000 i.e. (40 mg) ugotovili izpostavljenost anti-Xa, ki je bila pri ženskah z majhno telesno maso (< 45 kg) 52 % večja in pri moških z majhno telesno maso (< 57 kg) 27 % večja kot pri kontrolnih osebah z normalno telesno maso (glejte poglavje 4.4).
If you use more LOVENOX (and associated names) than you should If you think that you have used too much or too little LOVENOX (and associated names), tell your doctor, nurse or pharmacist immediately, even if you have no signs of a problem. 
Če ste uporabili večji odmerek zdravila LOVENOX (in povezana imena), kot bi smeli: Če menite, da ste uporabili preveč ali premalo zdravila LOVENOX (in povezana imena), nemudoma obvestite svojega zdravnika, medicinsko sestro ali farmacevta, tudi če nimate nobenih težav.
• If you are allergic to heparin or other low molecular weight heparins such as nadroparin, tinzaparin or dalteparin. 
• Če ste alergični na heparin ali druge nizkomolekularne heparine, npr. na nadroparin,
Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon 
Opredelitev pogostnosti je: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do
Based on literature data the use of enoxaparin sodium 4,000 IU (40 mg) in cirrhotic patients (ChildPugh class B-C) appears to be safe and effective in preventing portal vein thrombosis. 
Glede na podatke iz literature je uporaba 4.000 i.e. (40 mg) natrijevega enoksaparinata pri bolnikih s cirozo (Child-Pugh B-C) varna in učinkovita za preprečevanje portalne venske tromboze.
LOVENOX (and associated names) can be used for two different types of heart attack called STEMI (ST segment elevation myocardial infarction) or Non-STEMI (NSTEMI). 
Zdravilo LOVENOX (in povezana imena) se lahko uporablja za dve različni vrsti srčnega infarkta: STEMI (srčni infarkt z dvigom spojnice ST) ali ne-STEMI (NSTEMI).
The treatment benefits of enoxaparin sodium, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35 percent reduction in the relative risk of myocardial reinfarction, as compared with treatment with unfractionated heparin (p<0.001). 
Koristi zdravljenja z natrijevim enoksaparinatom, ki so se kazale s številnimi izidi učinkovitosti, so se pojavile po 48 urah: ob tem času je bilo relativno tveganje za ponovni miokardni infarkt 35 odstotkov manjše kot z nefrakcioniranim heparinom (p < 0,001).
• Pregnant women with mechanical prosthetic heart valves The use of enoxaparin sodium for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. 
• Nosečnice z mehaničnimi protetičnimi srčnimi zaklopkami Uporaba natrijevega enoksaparinata za tromboprofilakso pri nosečnicah z mehaničnimi protetičnimi srčnimi zaklopkami ni ustrezno raziskana.
What LOVENOX (and associated names) is and what it is used for What you need to know before you use LOVENOX (and associated names) How to use LOVENOX (and associated names) Possible side effects 
Kaj je zdravilo LOVENOX (in povezana imena) in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo LOVENOX (in povezana imena) Kako uporabljati zdravilo LOVENOX (in povezana imena)
LOVENOX (and associated names) can be used during breastfeeding. 
Zdravilo LOVENOX (in povezana imena) se lahko uporablja med obdobjem dojenja.
This medicinal product is authorised in the Member States of the EEA under the following names: {Name of the Member State} {Name of the medicinal product} {Name of the Member State} {Name of the medicinal product} [See Annex I - To be completed nationally] [For referral procedures, as appropriate] This leaflet was last revised in {MM/YYYY} {month YYYY}. 
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni: {Ime države članice}{Ime zdravila}
Enoxaparin sodium is a biological substance obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. 
Natrijev enoksparinat je biološka snov, dobljena z alkalno depolimerizacijo heparinovega benzilestra,
1) Stopping existing blood clots from getting any bigger. 
1) Ustavi povečevanje obstoječih krvnih strdkov.
Benzyl alcohol may also cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. 
Benzilalkohol lahko pri dojenčkih in otrocih do 3. leta starosti povzroči tudi toksične in anafilaktoidne reakcije.
• Extended prophylaxis of DVT following cancer surgery A double-blind, multicenter trial, compared a four-week and a one-week regimen of enoxaparin sodium prophylaxis in terms of safety and efficacy in 332 patients undergoing elective surgery for abdominal or pelvic cancer. 
Dvojno slepo multicentrično preskušanje je primerjalo štiritedensko in enotedensko shemo profilakse z natrijevim enoksaparinatom glede varnosti in učinkovitosti pri 332 bolnikih, ki so imeli opravljeno elektivno operacijo zaradi raka v trebuhu ali medeničnem predelu.
• If the patient is a premature or newborn baby up to 1 month because of the risk of severe toxicity including abnormal respiration (“gasping syndrome”). 
• Če je bolnik nedonošenček ali novorojenček, mlajši od 1 meseca, ker obstaja tveganje za hude toksične učinke, vključno z nenormalnim dihanjem ("sindrom hlastajočega dihanja").
• Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids. 
- zaviralci agregacije trombocitov, vključno z acetilsalicilno kislino v antiagregacijskih odmerkih (zaščita srca), klopidogrel, tiklopidin in antagonisti glikoproteina IIb/IIIa, ki so indicirani pri akutnem koronarnem sindromu, zaradi tveganja za krvavitve, - dekstran 40, - sistemski glukokortikoidi.
No dose reduction is necessary in the elderly patients in haemodialysis indication. 
Starejše osebe Starejšim bolnikom odmerka ni treba zmanjšati za hemodializno indikacijo.